asco xAmerican Society of Clinical Oncology (ASCO)
2015 Annual Meeting

May 29 - June 2, 2015

McCormick Place
Chicago, IL USA


ASCO - Poster: Randomized phase-2 study of sipuleucel-T with or without radium-223 in men with asymptomatic/minimally symptomatic bone-metastatic castrate-resistant prostate cancer

CHICAGO, IL USA (UroToday.com) - Presented by Jong Chul Park, A. Oliver Sartor, Rana Sullivan, Serina King, and Emmanuel S. Antonarakis at the American Society of Clinical Oncology (ASCO) Annual Meeting - Illumination & Innovation: Transforming Data into Learning - May 29 - June 2, 2015 - Chicago, Illinois USA

ASCO - Poster: Radium-223 in an international early access program (EAP): Effects of concomitant medication on overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients

CHICAGO, IL USA (UroToday.com) - Presented by Fred Saad, Joan Carles, Silke Gillessen, Daniel Heinrich, Jeremy Gratt, Kurt Miller, Sten Nilsson, Joe O'Sullivan, Marcello Tucci, Manfred Wirth, and Axel Heidenreich at the American Society of Clinical Oncology (ASCO) Annual Meeting - Illumination & Innovation: Transforming Data into Learning - May 29 - June 2, 2015 - Chicago, Illinois USA

ASCO - TROG 03.06 and VCOG PR 01-03: The "timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)" collaborative randomised phase III trial - Session Highlights

CHICAGO, IL USA (UroToday.com) - Dr. Gillian Duchesne, a radiation oncologist from the Peter MacCallum Cancer Center in Melbourne, Australia, presented the initial results of the TOAD study, a phase III randomized clinical trial assessing the timing of androgen deprivation therapy (ADT) among asymptomatic men with biochemical recurrence of prostate cancer.

ASCO - A phase III protocol of androgen suppression and radiotherapy vs. AS and RT followed by chemotherapy with docetaxel and prednisone for localized, high-risk prostate cancer - Session Highlights

CHICAGO, IL USA (UroToday.com) - Dr. Howard Sandler of Cedars-Sinai presented the results of RTOG 0521. The study sought to improve outcomes associated with treatment of locally advanced or high-risk localized prostate cancers that traditionally have a high risk of recurrence despite the use of standard of care radiotherapy and 2-3 years of concurrent androgen deprivation therapy (ADT).

ASCO - First-ever evidence shows adjuvant chemotherapy improves overall survival in high-risk, localized prostate cancer - Session Highlights

CHICAGO, IL USA (UroToday.com) - Adding docetaxel to standard hormone and radiation therapy reduced the risk of death for men with high-risk, localized prostate cancer in results reported at the 2015 ASCO Annual Meeting, in Chicago, IL.  At a median follow-up of 5.5 years in this phase III study RTOG 0521, overall survival (OS) rates were 93% in the docetaxel-treated group vs. 89% in the standard therapy group.

ASCO - Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE - Session Highlights

CHICAGO, IL USA (UroToday.com) - Dr. Nicholas James presented the initial survival results from the STAMPEDE study of men with metastatic or biochemical recurrent hormone sensitive prostate cancer.

ASCO - Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration resistant prostate cancer - Session Highlights

CHICAGO, IL USA (UroToday.com) - Dr. Howard Scher of Memorial Sloan Kettering presented the Prostate Cancer Working Group 3 (PCWG3) Consensus Guidelines, an update from the previously published Prostate Cancer Working Group 2 (PCWG2) set published in 2008.

Page 1 of 3
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe